報價延遲最少15分鐘:2026/03/22 00:45 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.4 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.14/-0.72
|
|
企業價值
272.01M
|
| 資產負債 |
|
每股賬面淨值
0.13
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
5.00M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage. |
